Copyright © 2021. Inderes Oyj. All rights reserved.

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Cantargia reported their Q1 this morning with an operating loss of SEK -73.2m, 45% more than we expected (SEK -50.5m) and up 83% from last year (SEK -39.9m). The increased spending is attributable to the increased investments in research and development; the extension of the CANFOUR phase II study and the initiation of more value-adding studies to broaden Cantargia’s oncology pipeline as well as in autoimmune/inflammatory diseases. We will address the recent CMD in our review tomorrow.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.